Clinical trials: Esomeprazole, completed
Healthy
A Healthy Female and Male Volunteers Aspirin Study
This is a study to compare the bioavailability of Acetyl Salicylic Acid (ASA) between Esomeprazole and Aspirin after multiple dose administration.
- Trial name
- NCT01448031
- Testing
- Capsule ASA 81mg/esomeprazole 20mg, Acetylsalicylzuur Apotex Cardio
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
GERD
A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects
A Study to compare pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects
- Trial name
- NCT03444402
- Testing
- CKD-381(formulation I), CKD-381(formulation II), D026(Nexium 40mg)
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Osteoarthritis
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
We will evaluate the efficacy of PN 400 and an active comparator in patients that have Osteoarthritis of the knee.
- Trial name
- NCT00665431
- Testing
- PN 400 (VIMOVO), celebrex, Rescue Antacid
- Where
- United States
- Volunteers
- 610 people
- Sponsor
- POZEN
Gastroesophageal Reflux Disease (GERD)
Phase 3/Safety & Efficacy of Esomeprazole in Infants
The purpose of this study is to look at the improvement of a once a day dose of esomeprazole for reducing the signs and symptoms of infants with gastroesophageal reflux disease (GERD).
- Trial name
- NCT00468559
- Testing
- Open Label Run In Esomeprazole, Double Blind Esomeprazole
- Where
- 25 sites in United States, France and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Heartburn
To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 40 mg to subjects who still had heartburn after receiving rabeprazole 20 mg once daily for 4 to 8 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Trial name
- NCT01249651
- Testing
- esomeprazole 40 mg
- Where
- China
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Healthy
Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects
First in human study
- Trial name
- NCT01007019
- Testing
- YH4808 30mg, YH4808 50mg, YH4808 100mg
- Where
- South Korea
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Gastrointestinal Disease, Signs and Symptoms, Digestive
Nexium Dyspepsia/AST
The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment…
- Conditions
- Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia
- Trial name
- NCT00251992
- Testing
- Esomeprazole
- Where
- 183 sites in Austria, Belgium and 11 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Gastric Ulcer, Duodenal Ulcer
Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)
The purpose of this study is to compare the effect of esomeprazole 20 or 40 mg once daily versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low-dose acetylsalicylic acid.
- Trial name
- Oberon (NCT00441727)
- Testing
- Esomeprazole 40 mg, Esomeprazole 20 mg
- Where
- 189 sites in United States, Argentina and 18 more
- Volunteers
- 2,426 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
The purpose of this study is to demonstrate the efficacy of CJ-12420, once daily (QD), compared to esomeprazole in patients with erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8
- Trial name
- NCT02456935
- Testing
- CJ-12420 100 mg QD, Esomeprazole 40 mg QD
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- HK inno.N Corporation
NSAID Induced Gastropathy
Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy
Primary objective: To determine the levels of malondialdehyde (MDA) and immunohistochemistry surrogate of inflammation in patients with NSAID-induced gastric mucosal injury treated with Rebamipide 3x a day vs Esomeprazole 40mg…
- Trial name
- NCT00641004
- Testing
- Rebamipide and Esomeprazole
- Where
- 4 sites in Philippines
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical, Inc., Philippines
Healthy
Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects
This study is intended to evaluate whether intravenous (iv) esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®
- Trial name
- NCT00230516
- Testing
- Nexium, Prevacid
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.
This two-group study will investigate the effect of food (Group 1) and esomeprazole (Group 2) on the single oral dose pharmacokinetics of alectinib in healthy volunteers.
- Trial name
- NCT02023125
- Testing
- Alectinib, Esomeprazole, High Fat and Calorie Meal
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Erosive Esophagitis
Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)
A randomized, double-blind, double-dummy, active comparator, multi-centers, non-inferiority design clinical trial to assess the efficacy and safety of YYD601 in ERD patients (phase 3).
- Trial name
- NCT03943992
- Testing
- YYD601 40mg, Nexium 40mg
- Where
- South Korea
- Volunteers
- 170 people
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Chronic Hepatitis B
A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults
This study is designed to assess 1) the effect of multiple doses of itraconazole (CYP3A4 inhibitor), rifampin (CYP3A4 inducer), and esomeprazole (pH modifier) on the pharmacokinetics of a single oral dose of ABI-H2158, and 2) the…
- Trial name
- NCT04142762
- Testing
- ABI-H2158, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Gastroesophageal Reflux Disease
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.
- Trial name
- NCT02860624
- Testing
- 10 mg ilaprazole, 40mg esomeprazole
- Volunteers
- 550 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Gastroesophageal Reflux Disease
A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a…
- Trial name
- NEON (NCT00734097)
- Testing
- Esomeprazole 40 mg, Physical Exam, Quality of Life Questionnaires
- Where
- 10 sites in Argentina, Chile and 2 more
- Volunteers
- 314 people
- Sponsor
- AstraZeneca
Healthy Participants
Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
Study to determine the effect of multiple-dose BBT-877 on the single-dose pharmacokinetics of midazolam, the safety and tolerability of a single dose of BBT-877 administered alone and with multiple doses of itraconazole, and the…
- Trial name
- NCT04138836
- Testing
- BBT-877, Midazolam, Itraconazole
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bridge Biotherapeutics, Inc.
Healthy
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po
This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to…
- Trial name
- NCT00206050
- Testing
- Esomeprazole, pantoprazole
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Erosive Gastroesophageal Reflux Disease
Efficacy and Safety of HIP1601 Capsule
The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with erosive gastroesphageal reflux disease.
- Trial name
- NCT04080726
- Testing
- HIP1601, HGP1705
- Where
- South Korea
- Volunteers
- 213 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
GERD
Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease
The aim of this trial is to evaluate the complete remission of erosive gastroesophageal reflux disease with pantoprazole magnesium 40 mg once daily versus esomeprazole 40 mg once daily during four-week treatment with an extension…
- Trial name
- PAMES 0109 (NCT01132638)
- Testing
- Magnesium Pantoprazole, Magnesium Esomeprazole
- Where
- 9 sites in Brazil
- Volunteers
- 713 people
- Sponsor
- Takeda